CV · XBRL financial data

CapsoVision financial statements, every quarter

The same tables from 5 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

How these numbers work

Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
* marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
0 means a filing states zero; a dash (—) means no filing states that number.
“year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
Shares outstanding come from each filing's cover page, as of the date printed there.
Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

Fiscal quarters (CV's year ends in late December)

In thousands of dollars	Q2 FY25Jun 30, 2025	Q3 FY25Sep 30, 2025	Q4 FY25Dec 31, 2025	Q1 FY26Mar 31, 2026	Q2 FY26Jun 30, 2026
Revenue from contracts with customers	3,315	3,538	3,918*	2,792	3,643
Cost of goods and services sold	1,504	1,624	1,964*	1,463	1,772
Gross profit	1,811	1,914	1,954*	1,329	1,871
Research and development	3,392	6,090	5,721*	4,435	5,309
General and administrative	1,223	2,070	1,748*	1,896	2,206
Total operating expenses	6,462	9,933	9,418*	8,422	9,451
Operating income (loss)	(4,651)	(8,019)	(7,464)*	(7,093)	(7,580)
Other income (expense)	(11)	(34)	0*	1	17
Income tax expense (benefit)	0	0	24*	0	0
Net income (loss)	(4,625)	(7,921)	(7,394)*	(7,033)	(7,481)
Earnings per share, basic USD per share	(2.02)	(0.17)	—	(0.15)	(0.15)
Earnings per share, diluted USD per share	(2.02)	(0.17)	—	(0.15)	(0.15)
Weighted average shares, basic thousands of shares	2,292	46,217	—	47,457	49,938
Weighted average shares, diluted thousands of shares	2,292	46,217	—	47,457	49,938

Fiscal quarters (CV's year ends in late December)

In thousands of dollars	Q2 FY25Jun 30, 2025	Q3 FY25Sep 30, 2025	Q4 FY25Dec 31, 2025	Q1 FY26Mar 31, 2026	Q2 FY26Jun 30, 2026
Accounts receivable	1,854	1,870	2,498	1,925	2,265
Inventory	3,042	3,187	2,987	3,491	4,704
Prepaid and other current assets	1,837	1,201	1,072	1,151	1,234
Total current assets	7,799	24,045	16,669	24,500	17,280
Property and equipment, net	683	640	611	620	562
Right-of-use asset	1,024	935	843	749	651
Total assets	9,547	25,661	18,164	25,945	18,569
Accounts payable	1,157	1,345	1,143	1,359	475
Accrued liabilities	1,588	2,790	2,697	3,494	4,101
Total current liabilities	4,221	4,635	4,427	5,363	5,158
Lease liability, non-current	687	584	477	362	245
Total liabilities	4,908	5,219	4,904	5,725	5,403
Accumulated deficit	(140,350)	(148,271)	(155,665)	(162,698)	(170,179)
Total stockholders' equity	(138,986)	20,442	13,260	20,220	13,166
Total liabilities and equity	9,547	25,661	18,164	25,945	18,569
Common shares outstanding (cover page) thousands of shares	46,774	46,843	49,838	49,964	50,047

Fiscal quarters (CV's year ends in late December)

In thousands of dollars	Q2 FY25Jun 30, 2025	Q3 FY25Sep 30, 2025	Q4 FY25Dec 31, 2025	Q1 FY26Mar 31, 2026	Q2 FY26Jun 30, 2026
Net income (loss)	(4,625)	(7,921)	(7,394)*	(7,033)	(7,481)
Stock-based compensation	170*	307*	197*	334	577*
Depreciation and amortization	55	54	55*	56	58
Net cash from operating activities	(4,526)*	(5,666)*	(7,686)*	(6,066)	(8,403)*
Purchases of property and equipment	30*	12*	8*	48	0*
Net cash from investing activities	(30)*	(12)*	(8)*	(48)	0*
Net cash from financing activities	1,168*	22,387*	15*	13,952	(443)*

SIC 3845 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen

SIC 3845 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
Runway shows only for companies burning cash with under $10B of public float.
* marks a quarter worked out from the filing totals: for a 10-Q, the year-to-date total less the earlier one.

Company	Cash ($K)	Revenue, quarter ($K)	Operating cash flow, quarter ($K)	Shares outstanding	Runway	Quarter
CapsoVision	not reported	3,643	(8,403)*	50.0M	—	Q2 FY26 10-QJun 30, 2026
Nexgel	1,706	3,686	(2,197)*	9.7M	0.8 quarters	Q2 FY26 10-QJun 30, 2026
Spectral AI	14,000	3,524	(4,097)*	32.2M	3.4 quarters	Q2 FY26 10-QJun 30, 2026
Hyperfine	43,458	3,904	(7,268)*	not reported	6.0 quarters	Q2 FY26 10-QJun 30, 2026
LogicMark	3,496	3,349	83*	899,759	—	Q2 FY26 10-QJun 30, 2026
Medinotec	2,584	3,201	108*	11.8M	—	Q2 FY27 10-QAug 31, 2026
Biotricity	467	4,277	507	19.9M	—	Q1 FY27 10-QJun 30, 2026
Picard Medical	38	2,954	(1,352)*	2.3M	0.0 quarters	Q2 FY26 10-QJun 30, 2026
Allurion Technologies	5,056	2,947	(3,221)	15.0M	1.6 quarters	Q1 FY26 10-QMar 31, 2026

Not investment advice. Not affiliated with the U.S. SEC.